ClinicalTrials.gg
TerminatedNCT01838369Updated Jan 11, 2023

A Phase II Study of BI-505 in Smoldering Multiple Myeloma

A Phase 2 interventional study of BI-505 in Smoldering Multiple Myeloma, sponsored by BioInvent International AB. Terminated at 1 site in Sweden. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-01-11.

Sponsored by BioInvent International AB · Phase 2, Interventional, and Treatment

How we know

Why this study was terminated
Sponsor's decision

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
4
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

The purpose of this study is to investigate the effect of BI-505 on tumor burden in patients diagnosed with smoldering multiple myeloma.

02

Conditions studied

  • Smoldering Multiple Myeloma
03

In context

Smoldering Multiple Myeloma

101 studies on the registry are indexed under Smoldering Multiple Myeloma; 34 are open to participants now.

This study's enrollment of 4 is below the median of 31 across 71 interventional studies indexed under Smoldering Multiple Myeloma.

Browse Smoldering Multiple Myeloma studies →

Lead sponsor

BioInvent International AB is the lead sponsor of 11 studies on the registry; 3 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of Smoldering multiple myeloma based on the International Myeloma Working Group criteria:

    • Serum M-protein greater than or equal to 3 g/dL and/or bone marrow plasma cells greater than or equal to 10 percent.
    • Absence of end-organ damage such as lytic bone lesions, anemia, hypercalcemia or renal failure that can be attributed to a plasma cell proliferative disorder.
  • Male or female, 18 years or older.
  • (ECOG) Performance status of 0-1.

Exclusion criteria

Exclusion Criteria:

  • Patients with a diagnosis of symptomatic multiple myeloma or a clinical suspicion of an ongoing progression into symptomatic multiple myeloma.
  • Prior or current treatment having a proven or potential impact on myeloma cell proliferation or survival (including conventional chemotherapies, biological therapies, immunomodulatory drugs, or proteasome inhibitors), as judged by the Investigator.
  • Severe other conditions.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
4 participants (actual)

Study arms

  • Experimental
    BI-505

    Drug: BI-505

Interventions

06

What researchers measure

Primary outcomes

  1. To assess the change in disease activity measured as M-protein levels in serum/urine following BI-505 treatment compared to base line according to the International Myeloma Working Group (IMWG) uniform response criteria

    Time frame: M-protein will be measured at screening, prior to each dose and at end of study visit, for up to 19 weeks.

Secondary outcomes

  1. The clinical safety of BI-505 will be assessed by reporting the numbers of AEs, the severity and the relationship to IMP.

    Safety will be assessed by measuring the following clinical safety parameters; Adverse events, vital signs, clinical laboratory tests, ECG and immunogenicity.

    Time frame: At each visit and up to 28 days after the last dose.

  2. The pharmacokinetic profile of BI-505 will be determined by calculating the following pharmacokinetic parameters: AUC, % AUCex, Cmax, Tmax, CL, Vss and T1/2.

    Time frame: Up to 28 days after the last dose.

  3. The pharmacodynamics of BI-505 will be assessed by measuring soluble biomarkers and ICAM-1 saturation on bone marrow plasma cells.

    Time frame: Up to 28 days after the last dose.

  4. The immunogenicity profile of BI-505 will be assessed by measuring antibodies towards BI-505.

    Time frame: Prior to first dose and at 28 days after the final dose.

07

Study locations

1 site
  • Department of Hemtaology, Skåne University Hospital
    Lund, SE-22185, Sweden
08

References and documents

Publications

  • Wichert S, Juliusson G, Johansson A, Sonesson E, Teige I, Wickenberg AT, Frendeus B, Korsgren M, Hansson M. A single-arm, open-label, phase 2 clinical trial evaluating disease response following treatment with BI-505, a human anti-intercellular adhesion molecule-1 monoclonal antibody, in patients with smoldering multiple myeloma. PLoS One. 2017 Feb 3;12(2):e0171205. doi: 10.1371/journal.pone.0171205. eCollection 2017. PubMed 28158311 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2013, a primary completion of Dec 2014 and a completion of Dec 2014. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 26, 2013
First posted
Apr 24, 2013
Start
Mar 2013
Primary completionActual
Dec 2014
CompletionActual
Dec 2014
Last update
Jan 11, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 11, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01838369
Lead sponsor
BioInvent International AB
Responsible party
Sponsor
First posted
Apr 24, 2013
Start date
Mar 2013
Primary completion
Dec 2014
Completion
Dec 2014
Last update
Jan 11, 2023

Study contacts

Markus Hansson, MD, PhD
principal investigator · Department of Hematology,Skåne University Hospital

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in May 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Bersanlimab

Start the discussion